Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer

被引：2
|
作者：
Talwar, Ashna
Deshmukh, Ashish
Trivedi, Meghana
Aparasu, Rajender R.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4364
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4364
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C. -S.
    Wei, R.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    SWISS MEDICAL WEEKLY, 2022, 152 : 48S - 48S
  • [42] MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer
    Rastogi, Priya
    Toi, Masakazu
    Harbeck, Nadia
    Bourayou, Nawel
    Frenzel, Martin
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (04)
  • [43] Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2-Early Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S5 - S6
  • [44] Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2-high-risk breast cancer
    Sammons, Sarah
    Moore, Heather
    Cushman, Jaycee
    Hamilton, Erika
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 805 - 814
  • [45] Abemaciclib as adjuvant treatment for high-risk early breast cancer
    Andrades, Ana Ganfornina
    Caballero, Silvia Fenix
    Olid, Alba Salguero
    Emilio, Jesus Alegre Del-Rey
    FARMACIA HOSPITALARIA, 2024, 48 (02) : 75 - 78
  • [46] Adjuvant Therapy of HR+, HER2 Breast Cancer Prolonging Survival without invasive Disease in high-risk early Breast Cancer
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)
  • [47] Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study
    Rugo, Hope S.
    Kabos, Peter
    Beck, J. Thad
    Jerusalem, Guy
    Wildiers, Hans
    Sevillano, Elena
    Paz-Ares, Luis
    Chisamore, Michael J.
    Chapman, Sonya C.
    Hossain, Anwar M.
    Chen, Yanyun
    Tolaney, Sara M.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [48] COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE® TEST FOR POSTMENOPAUSAL WOMEN WITH HR+/HER2-NODE-POSITIVE EARLY BREAST CANCER IN CANADA
    Berdunov, V
    Richardson, R.
    Millen, S.
    VALUE IN HEALTH, 2022, 25 (07) : S371 - S371
  • [49] Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study
    Zhang, Qingyuan
    Shen, Kunwei
    Song, Chuan-gui
    Ouyang, Quchang
    Liu, Zhenzhen
    Liu, Qiang
    Feng, Jifeng
    Chiu, Joanne W. Y.
    Tang, Jinhai
    Jiang, Zefei
    Tseng, Ling-Ming
    Wang, Xiaojia
    Yang, Liu
    Qian, Chenxi
    Shao, Zhimin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [50] Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain
    Galve-Calvo, Elena
    Gonzalez-Haba, Eva
    Gostkorzewicz, Joana
    Martinez, Irene
    Perez-Mitru, Alejandro
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 773 - 790
12345